NOS2 as a prognostic biomarker for early-onset colorectal cancer based on public data and clinical validation analysis
Abstract Early-onset colorectal cancer (EOCRC) was characterized by strong aggressiveness and high malignancy. The aim of this study was to screen suitable biomarkers for patients with EOCRC. EOCRC from The Cancer Genome Atlas Program (TCGA) database and Gene Expression Mapping (GEO) database were u...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-02-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-88966-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823862453855846400 |
|---|---|
| author | Chaoqun Xing Lipeng Zhao Weiwei Zou Xie Peng Xiao-Liang Xing Jie Li |
| author_facet | Chaoqun Xing Lipeng Zhao Weiwei Zou Xie Peng Xiao-Liang Xing Jie Li |
| author_sort | Chaoqun Xing |
| collection | DOAJ |
| description | Abstract Early-onset colorectal cancer (EOCRC) was characterized by strong aggressiveness and high malignancy. The aim of this study was to screen suitable biomarkers for patients with EOCRC. EOCRC from The Cancer Genome Atlas Program (TCGA) database and Gene Expression Mapping (GEO) database were used to screen biomarkers for prognosis and treatment guidance. Clinical samples were used to verify the expression situation of these candidate biomarkers. The results showed the immune-related gene nitric oxide synthase 2 (NOS2) was independently associated with the poor prognosis of EOCRC patients in both TGCA and GEO database. The Immune Dysfunction and Exclusion (TIDE) analysis showed that multiple immunotherapy signatures, such as TIDE, Exclusion, and CAF, were difference among EOCRC patients with different risk scores, and significantly correlated with the expression of NOS2. Sensitivity analysis of chemotherapy drugs showed that NOS2 was significantly correlated with several chemotherapy drugs, such as MG.132_1862, BMS.754807_2171, and GEN.317_1926. Clinical validation analysis showed that the expression of NOS2 and its related genes CXCL1 and CXCL2 were significantly decreased in EOCRC patients. The results suggested that NOS2 can be used as a potential biomarker for EOCRC, which can be used for prognosis and guidance of immunotherapy and chemotherapy. |
| format | Article |
| id | doaj-art-11547f8374634594b78531e260d54d17 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-11547f8374634594b78531e260d54d172025-02-09T12:30:05ZengNature PortfolioScientific Reports2045-23222025-02-0115111210.1038/s41598-025-88966-6NOS2 as a prognostic biomarker for early-onset colorectal cancer based on public data and clinical validation analysisChaoqun Xing0Lipeng Zhao1Weiwei Zou2Xie Peng3Xiao-Liang Xing4Jie Li5The First Affiliated Hospital of Hunan Medical University, Hunan University of MedicineThe Second People’s Hospital of HuaihuaThe Second People’s Hospital of HuaihuaThe Second People’s Hospital of HuaihuaThe First Affiliated Hospital of Hunan Medical University, Hunan University of MedicineHunan University of MedicineAbstract Early-onset colorectal cancer (EOCRC) was characterized by strong aggressiveness and high malignancy. The aim of this study was to screen suitable biomarkers for patients with EOCRC. EOCRC from The Cancer Genome Atlas Program (TCGA) database and Gene Expression Mapping (GEO) database were used to screen biomarkers for prognosis and treatment guidance. Clinical samples were used to verify the expression situation of these candidate biomarkers. The results showed the immune-related gene nitric oxide synthase 2 (NOS2) was independently associated with the poor prognosis of EOCRC patients in both TGCA and GEO database. The Immune Dysfunction and Exclusion (TIDE) analysis showed that multiple immunotherapy signatures, such as TIDE, Exclusion, and CAF, were difference among EOCRC patients with different risk scores, and significantly correlated with the expression of NOS2. Sensitivity analysis of chemotherapy drugs showed that NOS2 was significantly correlated with several chemotherapy drugs, such as MG.132_1862, BMS.754807_2171, and GEN.317_1926. Clinical validation analysis showed that the expression of NOS2 and its related genes CXCL1 and CXCL2 were significantly decreased in EOCRC patients. The results suggested that NOS2 can be used as a potential biomarker for EOCRC, which can be used for prognosis and guidance of immunotherapy and chemotherapy.https://doi.org/10.1038/s41598-025-88966-6NOS2PrognosisImmuneTherapeuticEOCRC |
| spellingShingle | Chaoqun Xing Lipeng Zhao Weiwei Zou Xie Peng Xiao-Liang Xing Jie Li NOS2 as a prognostic biomarker for early-onset colorectal cancer based on public data and clinical validation analysis Scientific Reports NOS2 Prognosis Immune Therapeutic EOCRC |
| title | NOS2 as a prognostic biomarker for early-onset colorectal cancer based on public data and clinical validation analysis |
| title_full | NOS2 as a prognostic biomarker for early-onset colorectal cancer based on public data and clinical validation analysis |
| title_fullStr | NOS2 as a prognostic biomarker for early-onset colorectal cancer based on public data and clinical validation analysis |
| title_full_unstemmed | NOS2 as a prognostic biomarker for early-onset colorectal cancer based on public data and clinical validation analysis |
| title_short | NOS2 as a prognostic biomarker for early-onset colorectal cancer based on public data and clinical validation analysis |
| title_sort | nos2 as a prognostic biomarker for early onset colorectal cancer based on public data and clinical validation analysis |
| topic | NOS2 Prognosis Immune Therapeutic EOCRC |
| url | https://doi.org/10.1038/s41598-025-88966-6 |
| work_keys_str_mv | AT chaoqunxing nos2asaprognosticbiomarkerforearlyonsetcolorectalcancerbasedonpublicdataandclinicalvalidationanalysis AT lipengzhao nos2asaprognosticbiomarkerforearlyonsetcolorectalcancerbasedonpublicdataandclinicalvalidationanalysis AT weiweizou nos2asaprognosticbiomarkerforearlyonsetcolorectalcancerbasedonpublicdataandclinicalvalidationanalysis AT xiepeng nos2asaprognosticbiomarkerforearlyonsetcolorectalcancerbasedonpublicdataandclinicalvalidationanalysis AT xiaoliangxing nos2asaprognosticbiomarkerforearlyonsetcolorectalcancerbasedonpublicdataandclinicalvalidationanalysis AT jieli nos2asaprognosticbiomarkerforearlyonsetcolorectalcancerbasedonpublicdataandclinicalvalidationanalysis |